Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.72 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
| ▸ | DRD3 | P35462 | 3/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | HTR7 | P34969 | 2/20 | 0.44 |
| ▸ | HRH1 | P35367 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30471048 | 1.00 | LOXL2 (0.72) | LOXL2HDAC6SMN1; SMN2NPSR1IDO1 | |
| SCHEMBL584581 | 0.87 | LOXL2 (0.74) | LOXL2HDAC6SMN1; SMN2NPSR1IDO1 | |
| SCHEMBL4390136 | 0.85 | NPC1 (0.53) | LOXL2HDAC6SMN1; SMN2DRD2DRD3 | |
| SCHEMBL30209080 | 0.84 | LOXL2 (1.00) | LOXL2HDAC6SMN1; SMN2NPSR1IDO1 | |
| SCHEMBL21104587 | 0.84 | LOXL2 (0.70) | LOXL2HDAC6SMN1; SMN2NPSR1IDO1 | |
| SCHEMBL3248813 | 0.84 | LOXL2 (1.00) | LOXL2HDAC6SMN1; SMN2NPSR1IDO1 | |
| SCHEMBL9892808 | 0.84 | LOXL2 (0.70) | LOXL2HDAC6SMN1; SMN2NPSR1IDO1 | |
| SCHEMBL7461310 | 0.84 | LOXL2 (0.70) | LOXL2HDAC6SMN1; SMN2NPSR1IDO1 | |
| SCHEMBL20359852 | 0.82 | LOXL2 (0.62) | LOXL2HDAC6SMN1; SMN2NPSR1IDO1 | |
| SCHEMBL19953220 | 0.81 | LOXL2 (0.76) | LOXL2HDAC6SMN1; SMN2NPSR1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250163073-A1 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2025-05-22 | — | — | US | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-12264154-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-11-14 | — | — | US | disclosed |
| WO-2024220917-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-12077547-B2 | Aldose reductase inhibitors and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-09-03 | — | — | US | disclosed |
| US-20080090854-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| US-20080090854-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| US-20080090854-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| CN-101094830-A | Fused bicyclic carboxamide derivatives for use as CXCR2 inhibitors in the treatment of inflammation | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-12-26 | — | — | CN | disclosed |
| WO-2007107758-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007107758-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2007-09-27 | — | — | WO | disclosed |
| EP-1836158-A1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION | Sanofi-Aventis Deutschland GmbH (DE) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006069656-A1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-07-06 | — | — | WO | disclosed |
| CN-1009831-B | PROCESS FOR PREPARING HETEROCYCLE-OXO-2,3-DIAZANAPHTHYL-ACETIC ACID | PFIZER (US) | 1990-10-03 | — | — | CN | disclosed |
| CN-86108308-A | Heterocycle oxo-2 guanidine-acetic acid | — | 1987-07-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163073-A1 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | ALDOA, AKR1B1, AKR1C2 | LOXL2 310/4885HDAC6 2777/4885SMN1; SMN2 1667/4885 |
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT1, PRMT5, PRMT6 | LOXL2 3829/4885HDAC6 441/4885SMN1; SMN2 1498/4885 |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT9 | LOXL2 3694/4885HDAC6 688/4885SMN1; SMN2 1278/4885 |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT9 | LOXL2 3694/4885HDAC6 688/4885SMN1; SMN2 1278/4885 |
| US-12264154-B2 | Compounds and methods of use | F12, C1R, ABCG2 | LOXL2 3243/4885HDAC6 299/4885SMN1; SMN2 1943/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | LOXL2 3243/4885HDAC6 299/4885SMN1; SMN2 1943/4885 |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | LOXL2 1520/4885HDAC6 2483/4885SMN1; SMN2 1208/4885 |
| US-20080090854-A1 | CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR4 | LOXL2 1854/4885HDAC6 1597/4885SMN1; SMN2 4381/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | LOXL2 2140/4885HDAC6 815/4885SMN1; SMN2 1645/4885 |
| US-12077547-B2 | Aldose reductase inhibitors and methods of use thereof | ALDOA, AKR1B1, AKR1C2 | LOXL2 310/4885HDAC6 2777/4885SMN1; SMN2 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.